Fig. 4
From: CRISPR/Cas9 delivery by NIR-responsive biomimetic nanoparticles for targeted HBV therapy
In vitro effects of UCNPs-Cas9@CM on HBV gene editing. A T7E1 assay for editing HBV in HepG2.2.15 and HepAD38 cells after UCNPs-Cas9@CM treatment with/without NIR Irradiation. B Sequence analysis of PCR amplicons of HBV cccDNA from HepG2.2.15 cells after UCNPs-Cas9@CM treatment with NIR irradiation. C Representative images of sanger sequencing profiles (from top to bottom) represent the wild type and indel type, respectively. D–F qRT-PCR analysis of HBV 3.5 kb mRNA, intracellular HBV DNA and HBV cccDNA levels in HepG2.2.15 and HepAD38 cells after UCNPs-Cas9@CM treatment with NIR irradiation, PBS treatment was used as the control. G–H HBsAg and HBeAg levels in supernatants of HepG2.2.15 and HepAD38 cells after UCNPs-Cas9@CM treatment with NIR irradiation, PBS treatment was performed as a control. Data are shown as mean ± SD, **p < 0.01, ***p < 0.001